C4 Therapeutics, Inc. CCCC 深 滬
等待開盤 02-02 09:30:00 美东时间
1.90
-0.060
-3.06%
華盛通- 最 高1.96
- 今 開1.95
- 成交量 167.00万股
- 最 低 1.83
- 昨 收 1.96
- 總市值 1.35亿
- 52周最高 3.65
- 市盈率 靜 --
- 換手率 2.35%
- 52周最低 1.085
- 委 比 -87.15%
- 總股本 7117.08万
- 歷史最高 51.21
- 量 比 2.09
- 振 幅 6.63%
- 歷史最低 1.06
- 每 手 1
- 風險率 0.56%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多C4 Therapeutics Grants Stock Options to New Employee as Inducement
C4 Therapeutics Grants Stock Options to New Employee as Inducement C4 Therapeutics Inc. has granted a new employee non-qualified stock options to purchase 85,480 shares of the company’s common stock. The exercise price for these options is set at the closing price of C4 Therapeutics’ common stock on
01-27 05:01
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
C4 Therapeutics announced the grant of non-qualified stock options to purchase 85,480 shares to a new employee as an inducement for joining the company. The options, granted on January 26, 2026, have an exercise price equal to the closing price of C4T's common stock on the grant date and will vest over four years, with 25% vesting in the first year and the remaining in monthly installments. C4T is a clinical-stage biopharmaceutical company focuse...
01-26 21:01
C4 Therapeutics Unveils Multi-Year Cemsidomide Clinical Strategy
C4 Therapeutics ( ($CCCC) ) has provided an announcement. On January 14, 2026, ...
01-14 20:28
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways
C4 Therapeutics outlines key milestones for cemsidomide, a molecular glue degrader targeting IKZF1/3 in multiple myeloma, with Phase 2 MOMENTUM trial initiation in Q1 2026 and Phase 1b trial in combination with elranatamab in Q2 2026. Additionally, the company emphasizes its internal discovery strategy focused on inflammation, neuro-inflammation, and neuro-degenerative diseases, aiming to deliver up to three INDs by end of 2028. With a cash runwa...
01-14 12:00
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
2025-12-18 10:54
Barclays Maintains Overweight on C4 Therapeutics, Lowers Price Target to $5
Barclays analyst Etzer Darout maintains C4 Therapeutics (NASDAQ:CCCC) with a Overweight and lowers the price target from $10 to $5.
2025-12-18 01:36
期权扫描 | 特朗普新政All in机器人领域！特斯拉多张Call单飙升超4倍；微软期权放量近2倍
特朗普新政All in机器人领域！特斯拉公布重大技术突破，多张Call单飙升超4倍；微软期权放量近2倍；比特币重回9.3万美元，MSTR期权成交活跃>>
2025-12-04 13:48
TD Cowen Initiates Coverage On C4 Therapeutics with Buy Rating
TD Cowen analyst Tyler Van Buren initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Buy rating.
2025-12-02 20:20
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
C4 Therapeutics, Inc. (C4T) announced that its management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 3, 2025, at 3:25 pm ET in Coral Gables, Florida. A live webcast and replay will be available on the company’s Investor Relations website. C4T is a clinical-stage biopharmaceutical company focused on targeted protein degradation science to develop innovative therapies for difficult-to-treat dise...
2025-11-25 12:00
C4 Therapeutics files $400M mixed shelf offering
C4 Therapeutics (CCCC) has filed a shelf registration to offer up to $400M in securities. The offering may include common stock, preferred stock, debt securities, warrants, or units, in one or more co...
2025-11-22 06:15
